Comprehensive Summary of Preclinical and Clinical Data for Pacritinib Published in Drugs of the Future

    Comprehensive Summary of Preclinical and Clinical Data for Pacritinib
                       Published in Drugs of the Future

PR Newswire

SEATTLE, July 3, 2013

SEATTLE, July 3, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ
and MTA: CTIC) today announced that a comprehensive article summarizing
preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor,
authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the
journal Drugs of the Future 2013. The article reviews the preclinical
pharmacology and pharmacokinetics in addition to the safety and efficacy
results from the Phase 1 and 2 clinical studies of pacritinib in patients with
myelofibrosis and lymphoma.

The authors conclude that the clinical trials to date support the safety,
efficacy and predictable pharmacokinetic profile of pacritinib. The
hematological adverse events have been uncommon and no dose reductions for
thrombocytopenia were necessary in the Phase 2 studies. In the two studies
that enrolled patients with myelofibrosis, pacritinib led to disease response,
improvement in splenomegaly (enlargement of the spleen) and lowered white
blood cell count, and symptom reduction in patients with and without
thrombocytopenia, or low blood cell count.

The link to the publication is available at www.CellTherapeutics.com.

Pacritinib is currently being evaluated in a randomized Phase 3 clinical
trial, known as PERSIST-1, in patients with myelofibrosis. Because of
pacritinib's relative lack of bone marrow suppression, there are no study
entry restrictions due to thrombocytopenia or anemia and patients with
platelet and red blood cell transfusion dependence are allowed to enroll in
the ongoing PERSIST-1 trial. More details on this study can be found at
www.clinicaltrials.gov. Pacritinib has orphan drug designation in the United
States andEurope.

About Myelofibrosis

Myelofibrosis is classified as a myeloproliferative neoplasm and is a chronic
bone marrow disorder. Myelofibrosis is caused by the accumulation of malignant
bone marrow cells that triggers an inflammatory response, scarring the bone
marrow and limiting its ability to produce red blood cells prompting the
spleen and liver to take over this function. Symptoms that arise from this
disease include enlargement of the spleen, anemia, extreme fatigue and pain.
It is estimated that the prevalence of myelofibrosis is approximately 30,000
in the United States.^1 ^

About Pacritinib

Pacritinib is an oral, once-a-day, tyrosine kinase inhibitor (TKI) with dual
activity against JAK2 and FLT3.The JAK family of enzymes are a central
component in signal transduction pathways, which are critical to normal blood
cell growth and development as well as inflammatory cytokine expression and
immune responses. Mutations in these kinases have been shown to be directly
related to the development of a variety of blood related cancers including
myeloproliferative neoplasms, leukemia and lymphoma. Pacritinib may offer an
advantage over other JAK inhibitors through effective treatment of symptoms
while having less treatment-emergent thrombocytopenia and anemia than has been
seen in currently approved and in-development JAK inhibitors.

About Cell Therapeutics, Inc.

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company
committed to the development and commercialization of an integrated portfolio
of oncology products aimed at making cancer more treatable. CTI is
headquartered in Seattle, WA. For additional information and to sign up for
email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements that are made pursuant
to the Safe Harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements concerning the Company's
development and prospects. Such statements involve a number of risks and
uncertainties the outcome of which could materially and/or adversely affect
actual future results and the market price of CTI's securities. Specifically,
the risks and uncertainties that could affect the development of pacritinib
include risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general, and with pacritinib in particular,
including, without limitation, the potential failure of pacritinib to prove
safe and effective for the treatment of patients with myelofibrosis, either
alone or in combination regimens, as determined by the U.S. Food and Drug
Administration and/or the European Medicines Agency; that pacritinib may not
satisfy a medical need not currently addressed with existing non-selective
JAK1/JAK2 inhibitors; that adverse events from treatment with pacritinib may
not be controllable; that the PERSIST-1 clinical trial of pacritinib may not
occur as planned; that 270 patients may not enroll in the PERSIST-1 clinical
trial; that the second Phase 3 clinical trial of pacritinib may not occur as
planned; that CTI may not be able to successfully implement its plans,
strategies and objectives related to the development of pacritinib; that CTI
may not be able to continue to raise capital as needed to fund its operations
and other risks, including, without limitation, competitive factors,
technological developments, costs of developing, producing and selling
PIXUVRI, pacritinib and CTI's other product candidates; and the risk factors
listed or described from time to time in CTI's filings with the Securities and
Exchange Commission including, without limitation, CTI's most recent filings
on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not
intend to update or alter its forward-looking statements whether as a result
of new information, future events, or otherwise.

References:

1. MPN Research Foundation. Available at
http://www.mpnresearchfoundation.org/Primary-Myelofibrosis. Accessed May 2013.

Contacts:

CTI Media and Investor Contacts:

Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
invest@ctiseattle.com

In Europe

CTI Life Sciences Limited, Milan Branch

Laura Villa
E: CTI_EUInvestors@CTI-Lifesciences.com
T: +39 02 89659700
http://www.celltherapeutics.com/italiano

SOURCE Cell Therapeutics, Inc.

Website: http://www.celltherapeutics.com
 
Press spacebar to pause and continue. Press esc to stop.